DeepMed Research

Dovitinib

Generic Name: Dovitinib

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₁FN_₆O

CAS Number: 405169-16-6

Unique Ingredient Identifier: I35H55G906

Background: Dovitinib is an orally active small molecule that exhibits potent inhibitory activity against multiple RTKs involved in tumor growth and angiogenesis. Preclinical data show that dovitinib works to inhibit multiple kinases associated with different cancers, including acute myeloid leukemia (AML) and multiple myeloma. Chiron currently has three ongoing Phase I clinical trials for dovitinib.

Indication: Investigated for use/treatment in multiple myeloma and solid tumors.

Clinical Trials

Study of TKI 258 in Combination With Xeloda and Oxaliplatin in Advanced Colorectal and Gastric Cancer

Phase 1

Terminated

Conditions: Colorectal Cancer
Gastric Cancer

Interventions: Drug: Xeloda,
Drug: Oxaliplatin
Drug: TKI258

First Posted Date: 2016-03-28

Last Posted Date: 2016-03-28

Lead Sponsor: National Cancer Centre, Singapore

Target Recruit Count: 3

Registration Number: NCT02720926

Locations: 🇸🇬
National Cancer Centre singapore, Singapore, Singapore

Dovitinib in Combination With Imatinib in Patients With Gastrointestinal Stromal Tumors

Phase 1

Withdrawn

Conditions: Gastrointestinal Stromal Tumors

Interventions: Drug: dovitinib plus imatinib

First Posted Date: 2014-10-20

Last Posted Date: 2015-08-04

Lead Sponsor: Asan Medical Center

Registration Number: NCT02268435

An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective

Phase 2

Completed

Conditions: Solid Tumors

Interventions: Drug: dovitinib
Drug: fulvestrant

First Posted Date: 2014-04-17

Last Posted Date: 2018-03-01

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 12

Registration Number: NCT02116803

Locations: 🇪🇸
Novartis Investigative Site, Palma De Mallorca, Islas Baleares, Spain

Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors

Phase 2

Withdrawn

Conditions: Somatostatinoma
Gastrinoma
Glucagonoma
Insulinoma
Recurrent Islet Cell Carcinoma
Pancreatic Polypeptide Tumor

Interventions: Drug: dovitinib lactate
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2014-04-09

Last Posted Date: 2017-07-19

Lead Sponsor: Academic and Community Cancer Research United

Registration Number: NCT02108782

A Study of Dovitinib With Androgen Deprivation Therapy (ADT) in Patients With Metastatic Prostate Cancer Receiving Primary ADT

Phase 2

Withdrawn

Conditions: Prostate Cancer

Interventions: Drug: Standard ADT
Drug: Dovitinib

First Posted Date: 2014-02-19

Last Posted Date: 2015-01-19

Lead Sponsor: Oscar Goodman, Jr.

Registration Number: NCT02065323

Locations: 🇺🇸
Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States

Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer

Phase 1

Withdrawn

Conditions: Recurrent Pancreatic Cancer
Stage IV Pancreatic Cancer
Duct Cell Adenocarcinoma of the Pancreas
Stage III Pancreatic Cancer
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: dovitinib lactate
Drug: gemcitabine hydrochloride
Drug: paclitaxel albumin-stabilized nanoparticle formulation
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2014-01-29

Last Posted Date: 2015-01-09

Lead Sponsor: Roswell Park Cancer Institute

Registration Number: NCT02048943

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Dovitinib (TKI258) and Abiraterone Acetate in Metastatic Castrate-Resistant Prostate Cancer (mCRPC)

Phase 2

Terminated

Conditions: Prostate Cancer

Interventions: Drug: Dovitinib
Drug: Abiraterone Acetate
Drug: Prednisone

First Posted Date: 2013-11-26

Last Posted Date: 2019-03-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 4

Registration Number: NCT01994590

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Dovitinib (TKI258) in the Treatment of Patients With Relapsed Glioblastoma

Phase 1

Conditions: First or Second Recurrence of Glioblastoma

Interventions: Drug: Dovitinib

First Posted Date: 2013-10-30

Last Posted Date: 2016-04-19

Lead Sponsor: PD Dr. Martin Glas

Target Recruit Count: 12

Registration Number: NCT01972750

Locations: 🇩🇪
Department of Neurology and Center of Integrated Oncology, University Hospital Bonn, Bonn, Germany

An Open-label, Multicenter, Phase II Study of Dovitinib in Advanced Thyroid Cancer

Phase 2

Completed

Conditions: Thyroid Cancer

Interventions: Drug: Dovitinib

First Posted Date: 2013-10-17

Last Posted Date: 2014-12-02

Lead Sponsor: Yonsei University

Target Recruit Count: 40

Registration Number: NCT01964144

Locations: 🇰🇷
Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea, Republic of

Dovitinib Plus Docetaxel in Gastric Cancer

Phase 1

Completed

Conditions: Gastric Cancer

Interventions: Drug: Dovitinib and docetaxel

First Posted Date: 2013-08-13

Last Posted Date: 2017-07-14

Lead Sponsor: Asan Medical Center

Target Recruit Count: 14

Registration Number: NCT01921673

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy